Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issueSanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022 Share XSanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issuehttps://pharmaphorum.com/news/sanofi-eyes-2022-filing-for-haemophilia-drug-fitusiran-despite-safety-issue/
FDA rejects Novartis’ cholesterol drug after factory inspection issueNovartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster Share XFDA rejects Novartis’ cholesterol drug after factory inspection issuehttps://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/
FDA approves Alnylam’s ultra-rare disease drug OxlumoThe FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), Share XFDA approves Alnylam’s ultra-rare disease drug Oxlumohttps://pharmaphorum.com/news/fda-approves-alynlams-ultra-rare-disease-drug-oxlumo/
Sanofi/Alnylam’s haemophilia drug hits another safety speed-bumpSanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after Share XSanofi/Alnylam’s haemophilia drug hits another safety speed-bumphttps://pharmaphorum.com/news/sanofi-alnylans-haemophilia-drug-hits-another-safety-speed-bump/
Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcastAlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing Share XAlnylam, gene-silencing and biotech in 2020: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/alnylam-gene-silencing-biotech-2020/
Alnylam’s Anant Murthy on making it as a US biotech in EuropeAlnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how Share XAlnylam’s Anant Murthy on making it as a US biotech in Europehttps://pharmaphorum.com/r-d/views-analysis-r-d/alnylam-anant-murthy-on-making-it-as-a-us-biotech-in-europe/
UK patients get early access to Alnylam’s ultra-rare disease drug lumasiranThe UK’s regulator has granted early access to Alnylam’s ultra-rare disease drug lumasiran, allowing patients with primary hyperoxaluria Share XUK patients get early access to Alnylam’s ultra-rare disease drug lumasiranhttps://pharmaphorum.com/news/uk-patients-get-early-access-to-alnylams-ultra-rare-disease-drug-lumasiran/
Alnylam’s shares dip as analyst backs rival after rare disease data revealAlnylam has revealed the data that forms the basis of its filings for its latest potential rare disease Share XAlnylam’s shares dip as analyst backs rival after rare disease data revealhttps://pharmaphorum.com/news/alnylams-shares-dip-as-analyst-backs-rival-after-rare-disease-data-reveal/
Alnylam files its third RNAi drug lumasiran in rare kidney diseaseGene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 Share XAlnylam files its third RNAi drug lumasiran in rare kidney diseasehttps://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
